<DOC>
	<DOC>NCT01153620</DOC>
	<brief_summary>The primary objective of the study is to assess the antiseptic efficacy of Lavasept 0.04% when used as an antiseptic agent and to compare these with Ringers' solution in patients with acute traumatic wounds.</brief_summary>
	<brief_title>The Antiseptic Efficacy and Tolerability of Lavasept® 0.04% on Acute Traumatic Wounds</brief_title>
	<detailed_description />
	<mesh_term>Wounds and Injuries</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Anti-Infective Agents, Local</mesh_term>
	<mesh_term>Polyhexamethylene biguanide</mesh_term>
	<criteria>Patients with acute traumatic cut, crush, abrasion, bite or stab wounds Provision of voluntary consent to participate in the study, following a full explanation of the nature and purpose of the study, by signing the informed consent form approved by the Institutional Ethics Committee (IEC) prior to all evaluations Wounds that are a minimum of approximately 4 cm2 in size Ability to read and understand the German patient information sheet and informed consent form &lt; 18 years of age Pregnancy Immunosuppression Wounds caused by a burn Wounds that require treatment of hyaline cartilage, the central nervous system, peritoneum, meningae, inner / middle ear or inner eye Simultaneous participation in another clinical trial Wounds that require immediate surgical or medical treatment as well patients who are critically ill Patient with a known allergy to the active agent or any of the excipients Wounds that are &gt;3 cm in depth Wounds that have not received medical treatment for ≥6 hours Heavily bleeding wounds Open fractures, joints or tendons Wounds of the face</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Acute traumatic wounds</keyword>
</DOC>